Loading quotes...
Forecast
There is no analyst data available for this company.
Discussions in the community
There is no discussion about this asset yet.
Start discussionNews Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Financials
| (EUR) | June 2026 | YoY |
|---|---|---|
| Revenue | 273.64k | 31.73% |
| Gross profit | -1.06m | 7,884.14% |
| Net profit | -1.05m | 11.66% |
| EBITDA | -999.51k | 12.66% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €2.89m |
Number of shares | 126.39m |
52-week high/low | €0.16 - €0.0181 |
| Dividends | No |
Beta | 0.68 |
P/E ratio | -0.66 |
PEG ratio | -0.02 |
P/B ratio | 0.68 |
P/S ratio | 3.18 |
Company profile
NextCell Pharma AB, a biopharmaceutical company, engages in the research and development of novel stem cell therapies in Sweden. The company develops ProTrans, a drug candidate comprising stem cells primarily for treating autoimmune and inflammatory diseases. It also provides Cellaviva, a stem cell bank for the family-saving of stem cells from umbilical cord blood and umbilical cord tissue. NextCell Pharma AB was incorporated in 2014 and is based in Huddinge, Sweden.
| Name | NextCell Pharma AB |
| CEO | Mathias Svahn |
| Website | |
| IPO | 13/07/2017 |
| Employees | 24 |
